Contract wins round-up: Summit, Pinnacle, Eckoh

UK drug discovery company Summit has signed a technology licensing agreement with US pharmaceuticals colossus, Bristol-Myers Squibb.

UK drug discovery company Summit has signed a technology licensing agreement with US pharmaceuticals colossus, Bristol-Myers Squibb.

The US firm will use use Summit's proprietary Seglin technology to identify and develop drug candidates for up to ten targets across multiple therapeutic areas. Summit will receive a $100,000 technology access fee and is eligible for research, development and regulatory milestones of up to $30m per product, plus royalties on worldwide sales of products arising from the technology.

Start your trial of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up
Latest Videos FromMoneyWeek
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.